Clinical trial
Observation Study on the Efficacy and Safety of Hepatic Artery Embolization Combined With Radiofrequency Ablation for Hepatic Hemangioma: The Impact of Different Treatment Intervals
NCT07919860 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started January 2027. Observational study, 80 participants (estimated). Lead sponsor Beijing Tiantan Hospital. Primary measure: Tumour volume reduction rate.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Observation Study on the Efficacy and Safety of Hepatic Artery Embolization Combined With Radiofrequency Ablation for Hepatic Hemangioma: The Impact of Different Treatment Intervals
- Lead sponsor
- Beijing Tiantan Hospital
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- January 1, 2027
- Completion date
- December 31, 2029
- Enrollment
- 80 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them.
hepatic hemangioma
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Healthy volunteers
- No
- Study type
- Observational
- Lead sponsor
- Beijing Tiantan Hospital
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Short-interval group | radiofrequency ablation (RFA), transcatheter arterial embolization (TAE) | |
Show registry wordingRFA is performed at 10-14 days after TAE | ||
| Long-interval group | radiofrequency ablation (RFA), transcatheter arterial embolization (TAE) | |
Show registry wordingRFA is performed at 2-3 months after TAE | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Tumour volume reduction rate | 6 month and 12 month post RFA |
Lead sponsor's other trials
Beijing Tiantan Hospital, most recent start first.
+485 more trials